{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:40:33Z","timestamp":1792928433895,"version":"4.5.0"},"reference-count":182,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000769","name":"University of Oxford","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Although HIV infection can be managed with antiretroviral drugs, there is no cure and therapy has to be taken for life. Recent successes in animal models with HIV-specific broadly neutralising antibodies (bNAbs) have led to long-term virological remission and even possible cures in some cases. This has resulted in substantial investment in human studies to explore bNAbs as a curative intervention for HIV infection. Emerging data are encouraging, but suggest that combinations of bNAbs with other immunomodulatory agents may be needed to induce and sustain long-term viral control. As a result, a number of clinical trials are currently underway exploring these combinations. If successful, the impact for the millions of people living with HIV could be substantial. Here, we review the background to the use of bNAbs in the search for an HIV cure and how different adjunctive agents might be used together to enhance their efficacy.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1478703","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T01:10:31Z","timestamp":1730941831000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination"],"prefix":"10.3389","volume":"15","author":[{"given":"Carla","family":"Nel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Frater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1068664","article-title":"Global, regional, and national HIV\/AIDS disease burden levels and trends in 1990\u20132019: A systematic analysis for the global burden of disease 2019 study","volume":"11","author":"Tian","year":"2023","journal-title":"Front Public Health"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283324283","article-title":"The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals","volume":"24","author":"Ray","year":"2010","journal-title":"AIDS"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.1.51","article-title":"Changes in the risk of death after HIV seroconversion compared with mortality in the general population","volume":"300","author":"Bhaskaran","year":"2008","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32802ef30c","article-title":"Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy","volume":"21","author":"Lima","year":"2007","journal-title":"AIDS"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e1002183","DOI":"10.1371\/journal.pmed.1002183","article-title":"Patient-reported barriers to adherence to antiretroviral therapy: A systematic review and meta-analysis","volume":"13","author":"Shubber","year":"2016","journal-title":"PloS Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-011-9942-x","article-title":"Adherence to highly active antiretroviral therapy (HAART): a meta-analysis","volume":"15","author":"Ortego","year":"2011","journal-title":"AIDS Behav"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835c54b8","article-title":"Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa","volume":"27","author":"Palmer","year":"2013","journal-title":"AIDS"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix194","article-title":"Optimizing research to speed up availability of pediatric antiretroviral drugs and formulations","volume":"64","author":"Penazzato","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s10461-012-0364-1","article-title":"Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV","volume":"17","author":"MacDonell","year":"2013","journal-title":"AIDS Behav"},{"key":"B10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s11904-009-0026-8","article-title":"Pediatric adherence to HIV antiretroviral therapy","volume":"6","author":"Haberer","year":"2009","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30234-4","article-title":"Multi-stakeholder consensus on a target product profile for an HIV cure","volume":"8","author":"Lewin","year":"2021","journal-title":"Lancet HIV"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nm880","article-title":"Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells","volume":"9","author":"Siliciano","year":"2003","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.58444","article-title":"The DNA provirus hypothesis","volume":"192","author":"Temin","year":"1976","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.coi.2016.05.015","article-title":"Challenges and strategies for the eradication of the HIV reservoir","volume":"42","author":"Kimata","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.24.13193","article-title":"Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy","volume":"94","author":"Chun","year":"1997","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00498-1","article-title":"HIV-1 sanctuary sites-the role of membrane-associated drug transporters and drug metabolic enzymes","volume":"22","author":"Whyte-Allman","year":"2020","journal-title":"AAPS J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e32835fc68a","article-title":"Overcoming pharmacologic sanctuaries","volume":"8","author":"Cory","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-0898-8","article-title":"A quantitative approach for measuring the reservoir of latent HIV-1 proviruses","volume":"566","author":"Bruner","year":"2019","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190896","article-title":"Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir","volume":"216","author":"Gaebler","year":"2019","journal-title":"J Exp Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad381","article-title":"Measuring HIV reservoirs: Do we need to choose between quantity and quality","volume":"229","author":"Roux","year":"2023","journal-title":"J Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.09.020","article-title":"Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure","volume":"155","author":"Ho","year":"2013","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e1003174","DOI":"10.1371\/journal.ppat.1003174","article-title":"Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies","volume":"9","author":"Eriksson","year":"2013","journal-title":"PloS Pathog"},{"key":"B23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.chom.2019.06.005","article-title":"The landscape of persistent viral genomes in ART-treated SIV, SHIV, and HIV-2 infections","volume":"26","author":"Bender","year":"2019","journal-title":"Cell Host Microbe"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.686690","article-title":"Inducible HIV-1 reservoir quantification: clinical relevance, applications and advancements of TILDA","volume":"12","author":"Lungu","year":"2021","journal-title":"Front Microbiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/72318","article-title":"Protection of macaques against vaginal transmission of a pathogenic HIV-1\/SIV chimeric virus by passive infusion of neutralizing antibodies","volume":"6","author":"Mascola","year":"2000","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1086\/420833","article-title":"Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies","volume":"189","author":"Ferrantelli","year":"2004","journal-title":"J Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.75.17.8340-8347.2001","article-title":"Antibody protects macaques against vaginal challenge with a pathogenic R5 simian\/human immunodeficiency virus at serum levels giving complete neutralization in vitro","volume":"75","author":"Parren","year":"2001","journal-title":"J Virol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02547-6","article-title":"Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial","volume":"29","author":"Gunst","year":"2023","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2911","article-title":"Animal models for HIV\/AIDS research","volume":"10","author":"Hatziioannou","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.19.12321-12331.2005","article-title":"Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys","volume":"79","author":"Liang","year":"2005","journal-title":"J Virol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.24.15547-15555.2005","article-title":"Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag","volume":"79","author":"Casimiro","year":"2005","journal-title":"J Virol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/415331a","article-title":"Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity","volume":"415","author":"Shiver","year":"2002","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01590-5","article-title":"Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021","volume":"27","author":"Deeks","year":"2021","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30052-9","article-title":"Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting","volume":"6","author":"Julg","year":"2019","journal-title":"Lancet HIV"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000767","article-title":"Challenges of HIV therapeutic vaccines clinical trials design","volume":"17","author":"Bailon","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"B37","article-title":"Combination IL-15 therapy in a SHIV nhp model","author":"Lim","year":"2020","journal-title":"In: Anonymous Conf Retroviruses Opportunistic Infections; 2020"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1038\/s41467-022-31196-5","article-title":"Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques","volume":"13","author":"Walker-Sperling","year":"2022","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment","volume":"355","author":"El-Sadr","year":"2006","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-021-00569-8","article-title":"Analytical treatment interruption in HIV trials: statistical and study design considerations","volume":"18","author":"Zheng","year":"2021","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.10.1220","article-title":"A prospective trial of structured treatment interruptions in human immunodeficiency virus infection","volume":"163","author":"Fagard","year":"2003","journal-title":"Arch Intern Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200311070-00008","article-title":"Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients","volume":"17","author":"Papasavvas","year":"2003","journal-title":"AIDS"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2055-6640(20)30995-X","article-title":"50LB Central nervous system impact of vorinostat, hydroxychloroquine and maraviroc combination therapy followed by treatment interruption in individuals treated during acute HIV infection","volume":"2","author":"Kroon","year":"2016","journal-title":"J Virus Eradication"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.1.234-241.2001","article-title":"Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection","volume":"75","author":"Carcelain","year":"2001","journal-title":"J Virol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13063-022-06151-w","article-title":"The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection\u2014study protocol for a two-stage randomised phase II trial","volume":"23","author":"Lee","year":"2022","journal-title":"Trials"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030442","article-title":"Antiretroviral therapy interruption (ATI) in HIV-1 infected patients participating in therapeutic vaccine trials: surrogate markers of virological response","volume":"8","author":"Leal","year":"2020","journal-title":"Vaccines (Basel"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000484","article-title":"Lessons learned from HIV antiretroviral treatment interruption trials","volume":"13","author":"Wen","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2267825","DOI":"10.1080\/25787489.2023.2267825","article-title":"Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States","volume":"24","author":"Bilger","year":"2023","journal-title":"HIV Res Clin Pract"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jve.2022.100072","article-title":"Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection","volume":"8","author":"van Paassen","year":"2022","journal-title":"J Virus Erad"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02213-x","article-title":"In-depth virological and immunological characterization of HIV-1 cure after CCR5Delta32\/Delta32 allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Jensen","year":"2023","journal-title":"Nat Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.04.030","article-title":"Targeting the latent reservoir for HIV-1","volume":"48","author":"Sengupta","year":"2018","journal-title":"Immunity"},{"key":"B53","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.immuni.2012.01.014","article-title":"Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation","volume":"36","author":"Shan","year":"2012","journal-title":"Immunity"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32990-3","article-title":"Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial","volume":"395","author":"Fidler","year":"2020","journal-title":"Lancet"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03156-8","article-title":"Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs","volume":"76","author":"Sadowski","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/v12010084","article-title":"Block-and-lock strategies to cure HIV infection","volume":"12","author":"Vansant","year":"2020","journal-title":"Viruses"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.09.080","article-title":"In vivo suppression of HIV rebound by didehydro-cortistatin A, a \"Block-and-lock\" Strategy for HIV-1 treatment","volume":"21","author":"Kessing","year":"2017","journal-title":"Cell Rep"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e1010014","DOI":"10.1371\/journal.ppat.1010014","article-title":"Inhibition of the H3K27 demethylase UTX enhances the epigenetic silencing of HIV proviruses and induces HIV-1 DNA hypermethylation but fails to permanently block HIV reactivation","volume":"17","author":"Nguyen","year":"2021","journal-title":"PloS Pathog"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2017.07.020","article-title":"CRISPR-Cas based antiviral strategies against HIV-1","volume":"244","author":"Wang","year":"2018","journal-title":"Virus Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkt571","article-title":"Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells","volume":"41","author":"Qu","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.03.012","article-title":"In vivo excision of HIV-1 provirus by saCas9 and multiplex single-guide RNAs in animal models","volume":"25","author":"Yin","year":"2017","journal-title":"Mol Ther"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-014-3456-3","article-title":"Zinc finger nuclease: a new approach for excising HIV-1 proviral DNA from infected human T cells","volume":"41","author":"Qu","year":"2014","journal-title":"Mol Biol Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021563","article-title":"A CRISPR-cas cure for HIV\/AIDS","volume":"24","author":"Hussein","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.24","article-title":"CRISPR-cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape","volume":"24","author":"Wang","year":"2016","journal-title":"Mol Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e144486","DOI":"10.1172\/JCI144486","article-title":"CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication","volume":"131","author":"Tebas","year":"2021","journal-title":"J Clin Invest"},{"key":"B67","unstructured":"China jails 'gene-edited babies' scientist for three years\n          \n          2019"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.708227","article-title":"To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1","volume":"12","author":"Griffith","year":"2021","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.710044","article-title":"Can broadly neutralizing HIV-1 antibodies help achieve an ART-free remission","volume":"12","author":"Hsu","year":"2021","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/22221751.2020.1713707","article-title":"Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities","volume":"9","author":"Liu","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1309215110","article-title":"Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues","volume":"110","author":"West","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2008.11.012","article-title":"A method for identification of HIV gp140 binding memory B cells in human blood","volume":"343","author":"Scheid","year":"2009","journal-title":"J Immunol Methods"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1126\/science.1241144","article-title":"Antibodies in HIV-1 vaccine development and therapy","volume":"341","author":"Klein","year":"2013","journal-title":"Science"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0235-7","article-title":"Recent progress in broadly neutralizing antibodies to HIV","volume":"19","author":"Sok","year":"2018","journal-title":"Nat Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2021.10.008","article-title":"Single B cell technologies for monoclonal antibody discovery","volume":"42","author":"Pedrioli","year":"2021","journal-title":"Trends Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nature12744","article-title":"Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys","volume":"503","author":"Barouch","year":"2013","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4063","article-title":"Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques","volume":"22","author":"Hessell","year":"2016","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/nature14411","article-title":"Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e25829","DOI":"10.1002\/jia2.25829","article-title":"Broadly neutralizing monoclonal antibodies for HIV prevention","author":"Miner","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031738","article-title":"Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat Biotechnol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PloS Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.08.023","article-title":"Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity","volume":"158","author":"Bournazos","year":"2014","journal-title":"Cell"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000731","article-title":"An exploration of how broadly neutralizing antibodies might induce HIV remission: the 'vaccinal' effect","volume":"17","author":"Tipoe","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1038\/emi.2016.97","article-title":"Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play","volume":"5","author":"Lambour","year":"2016","journal-title":"Emerg Microbes Infect"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000748","article-title":"CD8 + T-cell responses in HIV controllers: potential implications for novel HIV remission strategies","volume":"17","author":"Rutishauser","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e141677","DOI":"10.1172\/JCI141677","article-title":"CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification","volume":"131","author":"Okoye","year":"2021","journal-title":"J Clin Invest"},{"key":"B90","doi-asserted-by":"publisher","first-page":"20140290","DOI":"10.1098\/rstb.2014.0290","article-title":"Effects of neutralizing antibodies on escape from CD8+ T-cell responses in HIV-1 infection","volume":"370","author":"Wikramaratna","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/nature21435","article-title":"Early antibody therapy can induce long-lasting immunity to SHIV","volume":"543","author":"Nishimura","year":"2017","journal-title":"Nature"},{"key":"B92","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/s2666-5247(21)00239-1","article-title":"Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial","volume":"3","author":"Gruell","year":"2022","journal-title":"Lancet Microbe"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan8848","article-title":"A randomized controlled safety\/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection","volume":"9","author":"Sneller","year":"2017","journal-title":"Sci Transl Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1967","article-title":"Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys","volume":"15","author":"Johnson","year":"2009","journal-title":"Nat Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00449","article-title":"Long-term delivery of an anti-SIV monoclonal antibody with AAV","volume":"11","author":"Martinez-Navio","year":"2020","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30003-7","article-title":"Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial","volume":"6","author":"Priddy","year":"2019","journal-title":"Lancet HIV"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01762-x","article-title":"Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial","volume":"28","author":"Casazza","year":"2022","journal-title":"Nat Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000764","article-title":"A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117","volume":"17","author":"Zacharopoulou","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01815-1","article-title":"Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial","volume":"28","author":"Julg","year":"2022","journal-title":"Nat Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.2217\/imt.09.70","article-title":"Toll-like receptor agonists in cancer therapy","volume":"1","author":"Adams","year":"2009","journal-title":"Immunotherapy"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00222-16","article-title":"A novel toll-like receptor 9 agonist, MGN1703, enhances HIV-1 transcription and NK cell-mediated inhibition of HIV-1-infected autologous CD4+ T cells","volume":"90","author":"Offersen","year":"2016","journal-title":"J Virol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-10-119","article-title":"Reactivation of latent HIV-1 in central memory CD4+T cells through TLR-1\/2 stimulation","volume":"10","author":"Novis","year":"2013","journal-title":"Retrovirology"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2009.04.019","article-title":"TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4+ T cells","volume":"389","author":"Thibault","year":"2009","journal-title":"Virology"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003174","article-title":"TLR8 activates HIV from latently infected cells of myeloid-monocytic origin directly via the MAPK pathway and from latently infected CD4+ T cells indirectly via TNF-\u03b1","volume":"186","author":"Schlaepfer","year":"2011","journal-title":"J Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.07.043","article-title":"Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice","volume":"158","author":"Halper-Stromberg","year":"2014","journal-title":"Cell"},{"key":"B106","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","volume":"563","author":"Borducchi","year":"2018","journal-title":"Nature"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010467","article-title":"HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys","volume":"18","author":"Moldt","year":"2022","journal-title":"PloS Pathog"},{"key":"B108","unstructured":"A Phase 2a Study to Evaluate the Safety and Tolerability of a Regimen of Dual Anti-HIV Envelope Antibodies, VRC07-523LS and CAP256V2LS, in a Sequential Regimen With a TLR7 Agonist, Vesatolimod, in Early Antiretroviral-Treated HIV-1 Clade C-Infected Women\n          \n          \n          2022"},{"key":"B109","unstructured":"An open label, single arm study of the safety and antiretroviral activity of the combination of 2 long-acting broadly neutralizing antibodies plus an IL-15 superagonist complex in ART-treated adults living with HIV during analytical treatment interruption\n          \n          \n          2022"},{"key":"B110","unstructured":"A Phase I Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption\n          \n          \n          2021"},{"key":"B111","unstructured":"Pilot Study on Innate Activation and Viral Control in HIV-Infected Adults Undergoing an Analytical Treatment Interruption After Administration of Pegylated Interferon Alpha 2b With Broadly HIV-1 Neutralizing Antibodies (3BNC117, 10-1074)\n          \n          \n          2020"},{"key":"B112","unstructured":"Combining a TLR9 Agonist With Broadly Neutralizing Antibodies for Reservoir Reduction and Immunological Control of HIV Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial\n          \n          \n          2019"},{"key":"B113","article-title":"BEAT2 PRIMARY TRIAL OUTCOMES: PEG-IFN-\u03b12B + 3BNC117 & 10-1074 IN CHRONIC HIV INFECTION","author":"Tebas","year":"2023"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.2174\/1570162033485186","article-title":"Chromatin remodeling and modification during HIV-1 Tat-activated transcription","volume":"1","author":"Pumfery","year":"2003","journal-title":"Curr HIV Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/38664","article-title":"Histone acetylation in chromatin structure and transcription","volume":"389","author":"Grunstein","year":"1997","journal-title":"Nature"},{"key":"B116","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1615\/critrevoncog.2015012997","article-title":"Histone deacetylases and mechanisms of regulation of gene expression","volume":"20","author":"Chen","year":"2015","journal-title":"Crit Rev Oncog"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-1951-3","article-title":"Systemic HIV and SIV latency reversal via non-canonical NF-kappaB signalling in vivo","volume":"578","author":"Nixon","year":"2020","journal-title":"Nature"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02570-7","article-title":"AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques","volume":"29","author":"Dashti","year":"2023","journal-title":"Nat Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-00010-x","article-title":"Reactivation of latent HIV moves shock-and-kill treatments forward","volume":"578","author":"Lichterfeld","year":"2020","journal-title":"Nature"},{"key":"B120","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1038\/s41591-022-02023-7","article-title":"Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b\/2a, randomized trial","volume":"28","author":"Gunst","year":"2022","journal-title":"Nat Med"},{"key":"B121","unstructured":"Early Administration of Latency Reversing Therapy and Broadly Neutralizing Antibodies to Limit the Establishment of the HIV-1 Reservoir During Initiation of Antiretroviral Treatment - a Randomized Controlled Trial\n          \n          \n          2017"},{"key":"B122","unstructured":"A Phase 2a, Randomized Study of Romidepsin With or Without 3BNC117 to Evaluate the Effects on the HIV-1 Reservoir (ROADMAP)\n          \n          \n          2017"},{"key":"B123","unstructured":"IGHID 11802 - Combination Therapy With the Novel Clearance Modality (VRC07-523LS) and the Latency Reversal Agent (Vorinostat) to Reduce the Frequency of Latent, Resting CD4+ T Cell Infection (The VOR-07 Study)\n          \n          \n          2019"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab487","article-title":"Stable latent HIV infection and low-level viremia despite treatment with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent vorinostat","volume":"225","author":"Gay","year":"2022","journal-title":"J Infect Dis"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0274-9","article-title":"CD8+ T cells in HIV control, cure and prevention","volume":"20","author":"Collins","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B126","first-page":"97","article-title":"Therapeutic HIV vaccines and broadly neutralizing antibodies","volume":"27","author":"Sobieszczyk","year":"2020","journal-title":"Top Antivir Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.2.1154-1163.2005","article-title":"Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein","volume":"79","author":"Gao","year":"2005","journal-title":"J Virol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fviro.2022.933418","article-title":"How to break free: HIV-1 escapes from innovative therapeutic approaches","volume":"2","author":"Magro","year":"2022","journal-title":"Front Virol (online"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2023.102774","article-title":"Conserved multiepitope vaccine constructs: A potent HIV-1 therapeutic vaccine in clinical trials","volume":"27","author":"Akbari","year":"2023","journal-title":"Braz J Infect Dis"},{"key":"B130","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.eclinm.2019.05.009","article-title":"Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)","volume":"11","author":"Mothe","year":"2019","journal-title":"EClinicalMedicine"},{"key":"B131","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41591-020-0774-y","article-title":"Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption","volume":"26","author":"Colby","year":"2020","journal-title":"Nat Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00823","article-title":"HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: safety, immunogenicity and effect on the viral reservoir (Study BCN02)","volume":"11","author":"Mothe","year":"2020","journal-title":"Front Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.trsl.2020.04.008","article-title":"Therapeutic vaccines for the treatment of HIV","volume":"223","author":"Chen","year":"2020","journal-title":"Transl Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2022.2059467","article-title":"Progress towards a therapeutic HIV DNA vaccine","volume":"21","author":"Munson","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000830","article-title":"The safety and immunogenicity of an interleukin-12-enhanced multiantigen DNA vaccine delivered by electroporation for the treatment of HIV-1 infection","volume":"71","author":"Jacobson","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit236","article-title":"Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery","volume":"208","author":"Kalams","year":"2013","journal-title":"J Infect Dis"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.007","article-title":"Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU((R))-Multi-HIVB, in untreated HIV-1 infected subjects","volume":"30","author":"Vardas","year":"2012","journal-title":"Vaccine"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e328363d3b7","article-title":"Nonreplicating vectors in HIV vaccines","volume":"8","author":"Johnson","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10091516","article-title":"Development of modified vaccinia virus ankara-based vaccines: advantages and applications","volume":"10","author":"Orlova","year":"2022","journal-title":"Vaccines (Basel"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq105","article-title":"Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles","volume":"203","author":"Goepfert","year":"2011","journal-title":"J Infect Dis"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24820-2","article-title":"Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines","volume":"8","author":"Altenburg","year":"2018","journal-title":"Sci Rep"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e32833d2d2b","article-title":"Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag\/pol\/nef subtype B HIV vaccine","volume":"5","author":"Gray","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis342","article-title":"Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)","volume":"206","author":"Duerr","year":"2012","journal-title":"J Infect Dis"},{"key":"B145","unstructured":"The Oxford\/AstraZeneca (ChAdOx1-S [recombinant] vaccine) COVID-19 vaccine: what you need to know\n          \n          2022"},{"key":"B146","volume-title":"Vaxzevria1 (COVID 19 vaccine (ChAdOx1 S [recombinant])","year":"2024"},{"key":"B147","unstructured":"HVTN 706\/ HPX3002\/ mosaico\n          \n          2024"},{"key":"B148","unstructured":"Phase 3 mosaic-based investigational HIV vaccine study discontinued following disappointing results of planned data review\n          \n          2023"},{"key":"B149","unstructured":"Janssen and global partners to discontinue phase 3 mosaico HIV vaccine clinical trial\n          \n          2023"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/nature12519","article-title":"Immune clearance of highly pathogenic SIV infection","volume":"502","author":"Hansen","year":"2013","journal-title":"Nature"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1935","article-title":"Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge","volume":"15","author":"Hansen","year":"2009","journal-title":"Nat Med"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0130-7","article-title":"Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound","volume":"24","author":"Okoye","year":"2018","journal-title":"Nat Med"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw2607","article-title":"A live-attenuated RhCMV\/SIV vaccine shows long-term efficacy against heterologous SIV challenge","volume":"11","author":"Hansen","year":"2019","journal-title":"Sci Transl Med"},{"key":"B154","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.it.2023.02.001","article-title":"Programming cytomegalovirus as an HIV vaccine","volume":"44","author":"Picker","year":"2023","journal-title":"Trends Immunol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111953","article-title":"Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2","volume":"142","author":"Granados-Riveron","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B156","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.15190\/d.2021.1","article-title":"First COVID-19 vaccines receiving the US FDA and EMA emergency use authorization","volume":"9","author":"Fortner","year":"2021","journal-title":"Discoveries (Craiova"},{"key":"B157","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.15190\/d.2022.9","article-title":"mRNA-based vaccine technology for HIV","volume":"10","author":"Fortner","year":"2022","journal-title":"Discoveries (Craiova"},{"key":"B158","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.omtn.2019.03.003","article-title":"Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and rhesus macaques","volume":"15","author":"Pardi","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu522","article-title":"Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion","volume":"211","author":"Bogers","year":"2015","journal-title":"J Infect Dis"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01574-5","article-title":"A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques","volume":"27","author":"Zhang","year":"2021","journal-title":"Nat Med"},{"key":"B161","unstructured":"A Phase 1, Randomized, Open-label Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants\n          \n          \n          2022"},{"key":"B162","unstructured":"A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good General Health\n          \n          \n          2021"},{"key":"B163","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-3-662-45024-6_2","article-title":"Inactivated viral vaccines","author":"Sanders","year":"2014","journal-title":"Vaccine Analysis: Strategies Principles Control"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-017-0176-5","article-title":"Killed whole-HIV vaccine; employing a well established strategy for antiviral vaccines","volume":"14","author":"Kang","year":"2017","journal-title":"AIDS Res Ther"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-016-0317-2","article-title":"First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses","volume":"13","author":"Choi","year":"2016","journal-title":"Retrovirology"},{"key":"B166","article-title":"A Phase I, Randomized, Observer-blinded, Placebo-controlled Clinical Study to Assess the Safety, Tolerability, and Immune Response of Killed-Whole HIV-1 Vaccine (SAV001-H) Administered Intramuscularly to Chronic HIV-1 Infected Patients Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART)","year":"2012"},{"key":"B167","first-page":"413","volume-title":"Plotkin's vaccines","author":"Girard","year":"2018"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M205862200","article-title":"Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design","volume":"277","author":"Joyce","year":"2002","journal-title":"J Biol Chem"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.09.037","article-title":"Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response","volume":"23","author":"Ho","year":"2005","journal-title":"Vaccine"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e32832e6184","article-title":"Challenges for structure-based HIV vaccine design","volume":"4","author":"Schief","year":"2009","journal-title":"Curr Opin HIV AIDS"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.03.063","article-title":"Long-term increase of CD4+ central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization","volume":"26","author":"Gudmundsdotter","year":"2008","journal-title":"Vaccine"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.10.030","article-title":"Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study","volume":"32","author":"Harrer","year":"2014","journal-title":"Vaccine"},{"key":"B173","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S1473-3099(13)70343-8","article-title":"Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial","volume":"14","author":"Pollard","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"B174","unstructured":"A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines DNA.HTI, MVA.HTI and ChAdOx1.HTI in Early Treated HIV-1 Positive Individuals\n          \n          \n          2017"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02060-2","article-title":"Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial","volume":"28","author":"Bail\u00f3n","year":"2022","journal-title":"Nat Med"},{"key":"B176","article-title":"Rebound Dynamics Following Immunotherapy with an HIV vaccine, TLR-9 agonist, and Broadly Neutralizing Antibodies","author":"Peluso","year":"2023"},{"key":"B177","unstructured":"Combinatorial Therapy With a Therapeutic Conserved Element DNA Vaccine, MVA Vaccine Boost, TLR9 Agonist and Broadly Neutralizing Antibodies: a Proof-of-concept Study Aimed at Inducing an HIV Remission\n          \n          \n          2020"},{"key":"B178","unstructured":"A Safety, Immunogenicity and Efficacy Phase 1\/2a Study of a Heterologous Ad26.Mos4.HIV, MVA-BN-HIV Vaccine Regimen Plus Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults on Suppressive ART\n          \n          \n          2022"},{"key":"B179","unstructured":"Safety and Efficacy of Broadly Neutralizing Antibodies Followed by Innate Immune Stimulation and Therapeutic Vaccination for the Induction of HIV Remission\n          \n          \n          2023"},{"key":"B180","article-title":"A Phase I\/IIa Randomized, Placebo-Controlled Trial of Conserved-Mosaic T-cell Vaccine in a Regimen With Vesatolimod and Broadly Neutralizing Antibodies in Adults Initiated on Suppressive Antiretroviral Therapy During Acute HIV-1","year":"2024"},{"key":"B181","article-title":"A Phase I\/IIa, Randomised Study to Evaluate the Safety and the Effectiveness of a Combination of Therapeutic Vaccine, Broadly Neutralising Antibody (10-1074), and the Latency Reversing Agent Romidepsin to Achieve a Remission of HIV Infection in Chronically HIV-infected Participants Under Stable Combined Antiretroviral Therapy","year":"2020"},{"key":"B182","article-title":"Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV): Safety and Efficacy of Broadly Neutralizing Antibodies Combined With Therapeutic Vaccination for the Induction of HIV Remission","year":"2024"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1478703\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T01:10:43Z","timestamp":1730941843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1478703\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":182,"alternative-id":["10.3389\/fimmu.2024.1478703"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1478703","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"article-number":"1478703"}}